Ascelia Pharma is trying to bring a new kind of liver scan drug to patients with serious kidney problems, as worries grow about today’s common MRI contrast agents. If approval and a hospital partner fall into place, the company could go from having no sales to building a second leg in rare cancer treatment—though setbacks or stronger rivals could change the story fast.Read more
Ascelia Pharma is betting that growing worries about the safety and environmental impact of today’s common MRI contrast dyes push hospitals toward its manganese-based alternative for cancer patients with kidney problems. The upside hinges on regulators signing off and the company landing a strong commercial partner before cash runs tight.Read more
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
